Cargando…
Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Cytomegalovirus (CMV) retinitis is a rare end-organ disease of CMV infection and is a marker of severe immunosuppression, especially in human immunodeficiency virus (HIV)-positive patients. In multiple myeloma (MM) patients, CMV retinitis has been reported in the post-transplant setting, with an inc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870699/ https://www.ncbi.nlm.nih.gov/pubmed/35200544 http://dx.doi.org/10.3390/curroncol29020044 |
_version_ | 1784656820417069056 |
---|---|
author | Zu, Cheng Xu, Yufeng Wang, Yiyun Zhang, Mingming Zhao, Houli Fang, Xiaoyun Huang, He Hu, Yongxian |
author_facet | Zu, Cheng Xu, Yufeng Wang, Yiyun Zhang, Mingming Zhao, Houli Fang, Xiaoyun Huang, He Hu, Yongxian |
author_sort | Zu, Cheng |
collection | PubMed |
description | Cytomegalovirus (CMV) retinitis is a rare end-organ disease of CMV infection and is a marker of severe immunosuppression, especially in human immunodeficiency virus (HIV)-positive patients. In multiple myeloma (MM) patients, CMV retinitis has been reported in the post-transplant setting, with an incidence lower than 0.2%, and in patients receiving lenalidomide. Here, we describe the first case of CMV retinitis in myeloma patients following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (BCMA CAR-T) cell therapy. In addition to CMV, the patient developed multiple infections including a mouth ulcer, pneumonia, and fungal enteritis. While the complete remission (CR) status of MM was maintained, he regained a visual acuity of 20/1000 after appropriate ophthalmologic treatment. This single case illustrates the potential of BCMA CAR-T therapy to induce profound humoral immunosuppression, and demonstrates an imperative need for an established standard of monitoring and prophylaxis of post-CAR-T infections. |
format | Online Article Text |
id | pubmed-8870699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88706992022-02-25 Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma Zu, Cheng Xu, Yufeng Wang, Yiyun Zhang, Mingming Zhao, Houli Fang, Xiaoyun Huang, He Hu, Yongxian Curr Oncol Case Report Cytomegalovirus (CMV) retinitis is a rare end-organ disease of CMV infection and is a marker of severe immunosuppression, especially in human immunodeficiency virus (HIV)-positive patients. In multiple myeloma (MM) patients, CMV retinitis has been reported in the post-transplant setting, with an incidence lower than 0.2%, and in patients receiving lenalidomide. Here, we describe the first case of CMV retinitis in myeloma patients following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (BCMA CAR-T) cell therapy. In addition to CMV, the patient developed multiple infections including a mouth ulcer, pneumonia, and fungal enteritis. While the complete remission (CR) status of MM was maintained, he regained a visual acuity of 20/1000 after appropriate ophthalmologic treatment. This single case illustrates the potential of BCMA CAR-T therapy to induce profound humoral immunosuppression, and demonstrates an imperative need for an established standard of monitoring and prophylaxis of post-CAR-T infections. MDPI 2022-01-24 /pmc/articles/PMC8870699/ /pubmed/35200544 http://dx.doi.org/10.3390/curroncol29020044 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Zu, Cheng Xu, Yufeng Wang, Yiyun Zhang, Mingming Zhao, Houli Fang, Xiaoyun Huang, He Hu, Yongxian Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma |
title | Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma |
title_full | Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma |
title_fullStr | Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma |
title_full_unstemmed | Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma |
title_short | Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma |
title_sort | cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor t cell therapy for relapsed/refractory multiple myeloma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870699/ https://www.ncbi.nlm.nih.gov/pubmed/35200544 http://dx.doi.org/10.3390/curroncol29020044 |
work_keys_str_mv | AT zucheng cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma AT xuyufeng cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma AT wangyiyun cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma AT zhangmingming cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma AT zhaohouli cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma AT fangxiaoyun cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma AT huanghe cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma AT huyongxian cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma |